Trial Profile

A clinical trial to investigate the combination of GLPG-2737 and Orkambi (ivacaftor/lumacaftor)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 27 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GLPG 2737 (Primary) ; Ivacaftor/lumacaftor (Primary)
Indications Cystic fibrosis
Focus Therapeutic Use

Most Recent Events

07 May 2026 According to Galapagos NV media release, Galapagos NV is now called Lakefront Biotherapeutics.
05 May 2022 According to a Galapagos media release, the company expects to start the triple combination study early next year 2023.
27 Jun 2017 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com